Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine I by McMurray, John J. V. et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
STUDY DESIGN PAPER
Dual angiotensin receptor and neprilysin
inhibition as an alternative to angiotensin-
converting enzyme inhibition in patients with
chronic systolic heart failure: rationale for and
design of the Prospective comparison of ARNI
with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure trial
(PARADIGM-HF)
John J. V. McMurray1*, Milton Packer2, Akshay S. Desai3, Jim Gong4,
Martin P. Lefkowitz4, Adel R. Rizkala4, Jean Rouleau5, Victor C. Shi4,
Scott D. Solomon3, Karl Swedberg6, and Michael R. Zile7, on behalf of the
PARADIGM-HF Committees and Investigators†
1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 2University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Brigham and Women’s Hospital,
Cardiovascular Medicine, MA, USA; 4Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; 5Universite´ de Montre´al, Institut de Cardiologie, Montre´al, Canada; 6University
of Gothenburg, Cardiovascular Medicine Department, Gothenburg, Sweden; and 7The Medical University of South Carolina and RHJ Department of Veterans Administration
Medical center, Charleston, SC, USA
Received 24 January 2013; accepted 8 February 2013; online publish-ahead-of-print 5 April 2013
Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart
failure (HF), such as the renin–angiotensin–aldosterone system (RAAS), potentially beneficial counter-regulatory
systems are also active in HF. These promote vasodilatation and natriuresis, inhibit abnormal growth, suppress the
RAAS and sympathetic nervous system, and augment parasympathetic activity. The best understood of these mediators
are the natriuretic peptides which are metabolized by the enzyme neprilysin. LCZ696 belongs to a new class of drugs,
the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides.
Methods Patients with chronic HF, NYHA class II– IV symptoms, an elevated plasma BNP or NT-proBNP level, and an LVEF
of ≤40% were enrolled in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortailty
and morbidity in Heart Failure trial (PARADIGM-HF). Patients entered a single-blind enalapril run-in period (titrated
to 10 mg b.i.d.), followed by an LCZ696 run-in period (100 mg titrated to 200 mg b.i.d.). A total of 8436 patients
tolerating both periods were randomized 1:1 to either enalapril 10 mg b.i.d. or LCZ696 200 mg b.i.d. The primary
outcome is the composite of cardiovascular death or HF hospitalization, although the trial is powered to detect a
15% relative risk reduction in cardiovascular death.
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Perspectives PARADIGM-HF will determine the place of the ARNI LCZ696 as an alternative to enalapril in patients with systolic
HF. PARADIGM-HF may change our approach to neurohormonal modulation in HF.
Trial
registration
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Introduction
Neurohormonal pathways are thought to be fundamentally import-
ant in the pathophysiology of heart failure.1,2 The belief that sus-
tained activation of certain neurohumoral pathways such as the
renin–angiotensin–aldosterone system (RAAS) and sympathetic
nervous system (SNS) is detrimental in heart failure underpins the
basis of therapy.3 The crucial importance of the RAAS is supported
by the beneficial effects of ACE inhibitors, ARBs, andmineralocortic-
oid receptor antagonists.4 Likewise, the benefits of beta-blockers
argue for a key role of the SNS.5 Although the focus of therapeutic
intervention has been on blocking these pathways thought to be
harmful in heart failure, potentially beneficial counter-regulatory
systems are also activated in heart failure. These pathways variously
promote vasodilatation and natriuresis, inhibit abnormal growth,
suppress the RAAS and SNS, inhibit the release and actions of vaso-
pressin, and augment the parasympathetic nervous system. The best
understood mediators exerting these actions are the natriuretic
peptides. The first of these to be described, A-type natriuretic
peptide (ANP), is secreted in response to atrial distension, activates
the ANPR-A receptor, increasing intracellular cyclic guanylate
monophosphate (cGMP), and is cleared by the ANPR-C receptor
and by the action of the enzyme neutral endopeptidase (NEP),
also known as neprilysin. 6–10 B-type natriuretic peptide, secreted
predominantly by the ventricles in response to increased wall
stress, exerts similar actions and is cleared in the same way.10
Augmentation of natriuretic peptides has been considered as a
therapeutic strategy in heart failure for over two decades.11,12
Because oral delivery of these peptides is ineffective and long-term
parenteral delivery is problematic, blockade of natriuretic peptide
breakdown, by inhibition of neprilysin, has been developed as an
alternative approach to increasing natriuretic peptides. Oral nepri-
lysin inhibitors, used in combination with ACE inhibitors, had fa-
vourable short-term effects on haemodynamic measurements
and exercise time in patients with heart failure, but were not devel-
oped further.12–14 Subsequently, a molecule that was both a nepri-
lysin and an ACE inhibitor, omapatrilat, was studied in both
hypertension and heart failure, but its development was terminated
because of an unacceptable incidence of angioedema.15–18 This
adverse effect was thought to occur because both ACE and nepri-
lysin break down bradykinin, which directly or indirectly can cause
angioedema, and because omapatrilat may also inhibit a third
enzyme metabolizing bradykinin, aminopeptidase P.19 Angiotensin
receptor neprilysin inhibitors (ARNIs) are a new class of drug
developed both to block the RAAS and augment natriuretic
peptides.20,21 By so doing, ARNIs have the potential to modulate
favourably the neurohormonal imbalance that characterizes heart
failure. Because RAAS blockade is achieved by antagonism of the
angiotensin II type 1 receptor, and not by inhibition of ACE (or
aminopeptidase P), it is hypothesized that the risk of angioedema
will not be increased.22 LCZ696 is the first ARNI to be tested in
patients, and here we describe the design of the Prospective com-
parison of ARNI with ACEI to Determine Impact on Global Mor-
talilty and morbidity in Heart Failure trial (PARADIGM-HF).
Trial design and methods
PARADIGM-HF is a randomized, double-blind, parallel group,
active-controlled, two-arm, event-driven trial comparing the long-
term efficacy and safety of enalapril and LCZ696 in patients with
chronic symptomatic heart failure and reduced EF (HF-REF). The
trial was designed by the academic members of the Executive
Committee in collaboration with Novartis personnel.
Patients
Entry criteria were as follows: (i) age 18 years or older and able to
give written informed consent; (ii) NYHA functional class II– IV; (iii)
LVEF ≤ 35% (initially this was ≤ 40% but changed in a protocol
amendment dated 15 December 2010); (iv) plasma BNP ≥150
pg/mL (or NT-proBNP ≥600 pg/mL) at the screening visit (Visit
1, Figure 1) or a BNP ≥100 pg/mL (or NT-proBNP ≥400 pg/mL)
and a hospitalization for heart failure within the last 12 months;
(v) treatment with a stable dose of an ACE inhibitor or an ARB
equivalent to enalapril 10 mg/day (see Table 1) for at least 4
weeks before the screening visit; and (vi) treatment with a stable
dose of a beta-blocker for at least 4 weeks prior to the screening
visit, unless contraindicated or not tolerated. Although not
required, the protocol specified that an aldosterone antagonist
should also be considered in all patients, taking account of renal
function, serum potassium, and tolerability. If given, the dose of al-
dosterone antagonist should be stable for at least 4 weeks prior to
the screening visit. The key exclusion criteria are listed in Table 2.
Study design
The study consists of four phases: (i) screening; (ii) single-blind ena-
lapril run-in; (iii) single-blind LCZ696 run-in; and (iv) randomized
double-blind treatment (Figure 1). The rationale for the active
run-in periods is explained in the Discussion.
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Screening (Visit 1)
At the screening visit, patient eligibility was assessed according to
the inclusion/exclusion criteria (including the criteria in Table 3).
Any local measurement of LVEF within the eligibility range made
within the past 6 months was acceptable provided there was no
subsequent LVEF measurement above it. Eligibility BNP (and
NT-proBNP), serum potassium, and estimated glomerular filtra-
tion rate (eGFR) were measured in a central laboratory.
Enalapril active run-in period (Visit 2)
At Visit 2, most eligible patients started 2 weeks of single-blind
treatment with enalapril 10 mg b.i.d. A lower dose of enalapril
(5 mg b.i.d.) was allowed for patients currently treated with an
ARB and for those taking a low dose of ACE inhibitor (see
Table 1) if the investigator was concerned that switching directly
to enalapril 10 mg b.i.d. might not be tolerated (e.g. because of
hypotension, renal dysfunction, and/or hyperkalaemia). These
patients were up-titrated to enalapril 10 mg b.i.d. after 1–2
weeks. Patients tolerating enalapril 10 mg b.i.d. as defined by the
criteria in Table 3 were eligible for Visit 3.
LCZ696 active run-in period (Visits 3 and 4)
At Visit 3, patients started single-blind treatment with LCZ696
100 mg b.i.d. After 1–2 weeks, the dose was up-titrated to
200 mg b.i.d., for a further 2–4 weeks.
Other heart failure medication (except for an ACE inhibitor or
ARB) was continued during the run-in periods.
Randomization to double-blind treatment (Visit 5)
Patients tolerating both enalapril 10 mg b.i.d. and LCZ696 200 mg
b.i.d., as defined by the criteria in Table 3, were randomized in a 1:1
ratio to double-blind treatment with either enalapril 10 mg b.i.d. or
LCZ696 200 mg b.i.d. Study visits occur every 2–8 weeks during
the first 4 months of the double-blind period and every 4
months thereafter (with additional unscheduled visits, at the dis-
cretion of the investigator).
There were two short washout periods during the run-in
periods to minimize the potential risk of angioedema due to over-
lapping ACE inhibition and NEP inhibition at Visit 3 and Visit 5: (i)
enalapril was stopped a day prior to starting LCZ696 at Visit 3 and
(ii) LCZ696 was stopped a day prior to starting randomized study
drug at Visit 5.
Monitoring of safety and tolerability during double-blind
period
Patients are assessed at each study visit for hyperkalaemia, symp-
tomatic hypotension, increase in serum creatinine, angioedema,
and other adverse events (AEs) and serious AEs. Patients who
can no longer tolerate the target dose of study drug can be down-
titrated to the lower dose at the investigator’s discretion (after
considering whether any other relevant non-disease-modifying
Figure 1 PARADIGM-HF study schema.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Minimum required pre-study daily doses of
commonly prescribed angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers
ACE
inhibitors
Minimum daily
dose
ARBs Minimum daily
dose
Enalapril 10 mg Candesartan 16 mg
Captopril 100 mg Eprosartan 400 mg
Cilazapril 2.5 mg Irbesartan 150 mg
Fosinopril 20 mg Losartan 50 mg
Lisinopril 10 mg Olmesartan 10 mg
Moexipril 7.5 mg Telmisartan 40 mg
Perindopril 4 mg Valsartan 160 mg
Quinapril 20 mg
Ramipril 5 mg
Trandolapril 2 mg
Zofenopril 30 mg
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therapy can be discontinued, e.g. a calcium channel or alpha-adre-
noceptor blocker in a hypotensive patient). The dose of back-
ground disease-modifying drugs, such as beta-blockers, should
not be reduced to facilitate maintenance of study drug. Every
attempt should be made to re-challenge the patients so as to main-
tain as many patients as possible on the target dose of study drug.
Collection and adjudication of potential angioedema
events
Potential angioedema cases are identified in two ways: (i) proactive
reporting of any events that resemble angioedema by site investi-
gators; and (ii) routine safety monitoring by the sponsor for
signs or symptoms suggestive of potential angioedema. All identi-
fied cases are submitted to an independent angioedema adjudica-
tion committee for a final decision.
Study objectives
Primary objectives
The purpose of this study is to evaluate the effect of LCZ696
200 mg b.i.d. compared with enalapril 10 mg b.i.d., in addition to
conventional heart failure treatment, in delaying time to first oc-
currence of either cardiovascular (CV) death or heart failure
hospitalization.
Secondary objectives
Secondary endpoints were to test whether LCZ696, compared with
enalapril, is superior: (i) in improving the Kansas City Cardiomyop-
athy Questionnaire (KCCQ) clinical summary score for heart
failure symptoms and physical limitations at 8 months;23 (ii) in delay-
ing the time to all-cause mortality; (iii) in delaying time to new onset
atrial fibrillation; and (iv) in delaying the time to first occurrence of
either: (a) a 50% decline in eGFR relative to baseline (i.e. Visit 5);
(b) .30 mL/min/1.73 m2 decline in eGFR relative to baseline to a
value ,60 mL/min/1.73 m2; or (c) reaching end-stage renal disease.
Exploratory objectives
These are listed in Table 4.
Study management and committees
PARADIGM-HF is conducted by Novartis AG under the guidance
and leadership of the Executive Committee. The National Leaders
of participating countries are listed in Appendix 1.
An independent, external Data Monitoring Committee (DMC)
(listed in Appendix 1) has been appointed to oversee the safety
of the patients and review the results of the interim analyses. An
Endpoint Adjudication Committee (listed in Appendix 1) is respon-
sible for classifying all deaths and for determining whether pre-
Table 2 Key exclusion criteria
1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), ARBs, or neprilysin inhibitors, as
well as known or suspected contraindications to the study drugs.
2. Previous history of intolerance to recommended target doses of ACEIs or ARBs.
3. Known history of angioedema.
4. Requirement for treatment with both ACEIs and ARBs.
5. Current acute decompensated heart failure (exacerbation of chronic heart failure manifested by signs and symptoms that may require intravenous
therapy).
6. Symptomatic hypotension and/or a systolic blood pressure ,100 mmHg at Visit 1 (screening) or ,95 mmHg at Visit 3 or at Visit 5 (randomization).
7. Estimated glomerular filtration rate (eGFR) ,30 mL/min/1.73 m2 at Visit 1 (screening), Visit 3 (end of enalapril run-in), or Visit 5 (end of LCZ696 run-in
and randomization) or .35% decline in eGFR between Visit 1 and Visit 3 or between Visit 1 and Visit 5.
8. Serum potassium .5.2 mmol/L at Visit 1 (screening) or .5.4 mmol/L at Visit 3 or Visit 5 (randomization).
9. Acute coronary syndrome, stroke, transient ischaemic attack, cardiac, carotid, or other major cardiovascular surgery, PCI, or carotid angioplasty within
the 3 months prior to Visit 1.
10. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1.
11. Implantation of a CRT device within 3 months prior Visit 1 or intent to implant a CRT.
12. History of heart transplant or on a transplant list or with LV assistance device.
13. History of severe pulmonary disease.
14. Diagnosis of peripartum- or chemotherapy-induced cardiomyopathy within the 12 months prior to Visit 1.
15. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to Visit 1.
16. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker.
17. Presence of haemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation.
18. Presence of other haemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis.
19. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including, but not
limited to, any of the following:
History of active inflammatory bowel disease during the 12 months before Visit 1.
Active duodenal or gastric ulcers during the 3 months prior to Visit 1.
Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2×
upper limit of normal at Visit 1, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt.
Current treatment with cholestyramine or colestipol resins.
20. Presence of any other disease with a life expectancy of ,5 years.
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specified endpoint criteria are met for the non-fatal events.
Another committee is adjudicating suspected cases of angioedema
in this and other trials using LCZ696 (listed in Appendix 1).
Statistical considerations
The estimated annual event rate for the primary endpoint in the
control (enalapril) arm of PARADIGM-HF was based on the Can-
desartan in Heart failure: Assessment of Reduction in Mortality and
morbidity (CHARM)-Added trial where the annual event rate for
the same composite was 16.6% in the placebo group (and 14.1%
in the candesartan group).25 Because patients are treated with a
higher dose of ACE inhibitor (or LCZ696 equivalent) in
PARADIGM-HF and a greater proportion were expected to
receive a beta-blocker and a mineralocorticoid antagonist, a
more conservative expected annual event rate of 14.5% was
chosen for sample size calculation. The annual CV mortality rate
of 7% was estimated from the CHARM-Added trial in a similar
manner. We also anticipated that the requirement for an elevated
BNP or NT-proBNP level at enrolment would ensure an adequate
event rate.
The sample size is based upon the CV mortality (although the
trial will continue until the required number of patients have
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Safety monitoring criteria that need to be met at screening, at the end of the enalapril run-in and at randomization
Parameter Screening visit (V1) End of enalapril run-in/randomization visit (V3 and 5)
Hyperkalaemia K+ ≤5.2 mmol/L K+ ≤5.4 mmol/L
Renal dysfunction eGFR ≥30 mL/min/1.73 m2 eGFR ≥30 mL/min/1.73 m2
No decrease of eGFR of .35% from Visit 1
Blood pressure No symptomatic hypotension No symptomatic hypotension
SBP ≥100 mmHg SBP ≥95 mmHg
Adverse events No postural symptoms or other AEs that preclude
continuation according to the investigator’s judgement
No postural symptoms or other AEs that preclude
continuation according to the investigator’s judgement
AE, adverse effect/event; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
Table 4 Exploratory objectives
To compare the effects of LCZ696 and enalapril on:
first occurrence of a composite of CV death, hospitalization for heart
failure, non-fatal myocardial infarction, non-fatal stroke, or
resuscitated sudden death
the number of patients hospitalized and number of hospital admissions
(all-cause and cause-specific)
days alive out of hospital at 12 months
the rate of decline in eGFR
time to ‘treatment failure’, defined as: the addition of a new drug,
intravenous treatment, or a persistent increase in dose of diuretic
dose (.1 month) for the treatment of worsening HF
a ‘clinical composite score’ (assessed by NYHA classification and
patient global assessment) at 8 months
time to new-onset diabetes mellitus
health-related quality of life, assessed by total score and individual
scores of the subdomains of the KCCQ and the EuroQol
5-dimensions scale24
the incidence of coronary revascularization procedures
the profile of pre-specified biomarkers (e.g. vascular, renal, collagen,
metabolism, and inflammatory biomarkers) from baseline to
pre-defined time points
health resource utilization, i.e. number of days/stays in the intensive
care unit and number of emergency room visits.
The pharmacokinetics of valsartan, AHU377, and LBQ657 will also be
characterized at steady state in patients receiving LCZ696 using
population modelling and/or non-compartmental based methods.
CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure;
KCCQ, Kansas City Cardiomyopathy Questionnaire.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Large trials in heart failure using enalapril
Trial n Target
dose (mg)
Mean/median
daily dose (mg)
CONSENSUS (1987)a 127 20 b.i.d. 18.429
SOLVD-T (1991)b 1285 10 b.i.d. 16.628
SOLVD-P (1992) 2111 10 b.i.d. 16.730
V-HeFT II (1991) 403 10 b.i.d. 15.031
NETWORK (1998)c 516 10 b.i.d. 17.932
Nanas et al. (2000)d 122 low 10 b.i.d. 17.933
126 high 30 b.i.d. 19.333
OVERTURE (2002) 2884 10 b.i.d. 17.717
CARMEN (2004) 190 E only 10 b.i.d. 16.834
191 E + C 10 b.i.d. 14.934
CIBIS-3 (2005)e 505 B first 10 b.i.d. 15.835
505 E first 10 b.i.d. 17.235
B, bisoprolol; C, carvedilol; E, enalapril.
aThe trial had no EF entry criterion. Of patients randomized to enalapril, 22% were
titrated to the target dose of 20 mg b.i.d.
bThe trial had an active (enalapril) run-in period; 49% reached the target dose.
cThe trial had no EF entry criterion. All patients had to tolerate a test dose of
2.5 mg enalapril.
dBy 3 months, 72.5% of patients in the 10 mg b.i.d. group reached target dose
compared with 32.5% in the 30 mg b.i.d. group.
eDuring the ‘enalapril-first’ monotherapy phase, 84% of patients were titrated to
the target dose.
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experienced CV death or heart failure hospitalization—see below).
A total of 1229 CV deaths are required to give 80% power to
detect a relative risk reduction of 15% in the LCZ696 group, com-
pared with the enalapril group. A total of 8000 patients are
required to accrue this number of events, assuming an annual
CV death rate of 7% in the enalapril group, with a mean follow-up
of 34 months.
Assuming an annual rate of CV death or heart failure hospitaliza-
tion in the enalapril group of 14.5%, and the same sample size and
follow-up period, at least 2410 patients are expected to experi-
ence a primary event. This means that PARADIGM-HF should
have.97% power to detect a relative risk reduction of 15% in
this composite.
A final statistical analysis plan will be developed prior to the end
of the study and treatment unblinding.
Study duration, interim analyses, and
early termination
As PARADIGM-HF is an event-driven trial, all randomized patients
will remain in the trial until 2410 patients have experienced a CV
death or heart failure hospitalization, unless the DMC recom-
mends that the study be stopped earlier for efficacy or safety
reasons. The total length of the trial will depend on the duration
of the patient recruitment period and the time taken to accrue
the pre-specified number of patients with a primary event. Cur-
rently, three interim efficacy analyses are planned when approxi-
mately one-third, one-half, and two-thirds of the primary events
have occurred. The one-sided significance level of a to be used
for the final analysis will be adjusted for the interim efficacy ana-
lyses to control the overall type I error at 2.5% (one-sided). A fu-
tility analysis will also be performed at each of these interim
analyses, permitting early termination of the trial for lack of
efficacy.
Safety considerations
In view of the limited exposure of patients with heart failure to
LCZ696 before the start of PARADIGM-HF, the DMC performed
a safety assessment after the first 100, 300, and 600 patients com-
pleted the run-in period and the number of patients exposed to
study drug was also limited to 600 until the DMC had evaluated
safety in the first 200 patients to complete 4 weeks of double-blind
therapy. Thus, this study employed a seamless design, incorporat-
ing ‘Phase II’ into a ‘Phase III’ outcomes trial, as considered further
in the Discussion. Further interim safety assessments are planned
twice a year.
Current status
The protocol was approved by the Ethics Committee/Institutional
Review Board affiliated to each investigative site. Patients started
enrolling in PARADIGM-HF on 8 December 2009. As of 17
January 2013, the study was fully enrolled, with 8436 validly rando-
mized patients at 985 centres in 47 countries distributed across all
major geographical regions.
The study is being conducted in accordance with Good Clinical
Practice, Declaration of Helsinki 2002. The trial has been regis-
tered on Clinicaltrials.gov, NCT01035255.
Discussion
A strategy of dual RAAS blockade and natriuretic peptide augmen-
tation is theoretically attractive in heart failure and was tried pre-
viously with the dual neprilysin/ACE inhibitor omapatrilat in the
Omapatrilat Versus Enalapril Randomized Trial of Utility in Redu-
cing Events trial (OVERTURE).17 Although omapatrilat did not
reduce the primary endpoint of death or hospitalization for
heart failure requiring intravenous treatment, compared with ena-
lapril 10 mg b.i.d., it was superior to enalapril in relation to the sec-
ondary endpoint of CV death or CV hospitalization. Furthermore,
when the effect of omapatrilat on the primary endpoint was eval-
uated, retrospectively, using the same definition of hospitalization
for heart failure as had been used in the Studies of Left Ventricular
Dysfunction Treatment-trial (SOLVD-Treatment), where the use
of intravenous therapy was not required for positive adjudication,
omapatrilat was superior to enalapril. Furthermore, administration
of a single, large, dose of omapatrilat once daily may have on the
one hand caused excessive post-dose hypotension and on the
other not provided complete 24 h RAAS blockade or 24 h nepri-
lysin inhibition. Ultimately, however, because omapatrilat caused an
unacceptable incidence of angioedema in patients with hyperten-
sion, its development was halted.18
LCZ696 is a first-in-class ARNI.20–22 After ingestion, LCZ696
delivers systemic exposure to AHU377, a neprilysin inhibitor
pro-drug, and valsartan, an ARB. AHU377 is then rapidly metabo-
lized by non-specific esterases to the active neprilysin inhibitor
LBQ657. LCZ696 causes dose-dependent increases in ANP,
plasma and urinary cGMP, plasma renin activity, and angiotensin
II, effects consistent with activation of the NPR-A receptor and
blockade of the angiotensin II type 1 receptor.20–22 In healthy
volunteers and patients with heart failure, a total daily dose of
400 mg of LCZ696 gives systemic exposure to valsartan similar
to Diovanw 320 mg daily. 20,26
Several features of the design of PARADIGM-HF are worthy of
discussion.
The patients included in PARADIGM-HF are similar to those
enrolled in SOLVD-Treatment, i.e. in NYHA class II– IV and with
an LVEF ≤ 35% (in most cases). However, PARADIGM-HF also
had natriuretic peptide entry criteria. We used a BNP entry thresh-
old of ≥150 pg/mL (or NT-proBNP ≥600 pg/mL) at Visit 1 or a
BNP ≥100 pg/mL (or NT-proBNP ≥400 pg/mL) if the patient
was hospitalized for heart failure within the last 12 months. This
is because BNP and NT-proBNP are powerful predictors of CV
events in patients with heart failure and are, therefore, useful in
helping select a higher risk population.27,28 This was necessary, in
the light of recent improvements in outcome in patients with
heart failure as a result of new drug and device therapies, to
ensure a realistic trial size, and a trial with adequate power to
show a modest but still important treatment effect. Note that
patients in PARADIGM-HF are required to be treated with a beta-
blocker unless contraindicated or not tolerated, and investigators
are encouraged to use a mineralocorticoid (aldosterone) receptor
antagonist, as indicated.
The choice of active comparator was based upon the SOLVD-
Treatment trial which was a pivotal ACE inhibitor mortality/mor-
bidity study in a broad spectrum of patients with HF-REF.29 In
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that trial, the target dose of enalapril was 10 mg b.i.d. and the mean
daily prescribed dose in patients taking enalapril was 16.6 mg. The
same target dose of enalapril was used in at least seven other large
heart failure trials (Table 5).30–36 These trials and another large
community study of.17 500 patients achieved a mean daily
dose of enalapril of between 15 and 18 mg.37 Two trials, which
had higher target doses (20 mg b.i.d. and 30 mg b.i.d.), achieved
only slightly greater average doses, with less than half of patients
titrated to target. Therefore, from a regulatory perspective, the
‘gold standard’ comparator for LCZ696 is enalapril 10 mg b.i.d.,
the most tested ACE inhibitor in HF-REF. Moreover, we anticipate
that achievement of a similar average dose to that attained in the
SOLVD-Treatment trial will be required, although in two more
recent trials where enalapril was used in addition to a beta-blocker
(which was rarely used in SOLVD-Treatment), a lower average
achieved dose of enalapril was attained.35,36
The choice of dose of LCZ696 was first and foremost based
on the need to achieve serum concentrations of valsartan equiva-
lent to those obtained with the Diovanw formulation of valsartan
160 mg b.i.d., the dose shown to be effective in Val-HeFT and
VALIANT.38,39 Secondly, the dose of LCZ696 also had to
achieve adequate inhibition of neprilysin. LCZ696 200 mg b.i.d.
achieves systemic exposure similar to valsartan 160 mg b.i.d.
and, at that dose, also achieves 90% of its maximum inhibition
of neprilysin and leads to sustained increases in plasma cGMP
concentrations in healthy volunteers.20,21 In addition, in patients
with hypertension, LCZ696 200 mg once daily lowered sitting
systolic (difference 5.3 mmHg) and diastolic (difference
3.0 mmHg) blood pressure more than valsartan 160 mg, an incre-
mental blood pressure-lowering effect attributed to neprilysin in-
hibition.21 Furthermore, in a proof-of-concept study in patients
with HF-PEF, the Prospective comparison of ARNi with ARB
on Management Of heart failUre with preserved ejectioN fraction
trial (PARAMOUNT), LCZ696 200 mg b.i.d., compared with val-
sartan 160 mg b.i.d., led to a sustained reduction over 36 weeks
in plasma NT-proBNP concentration (a marker of LV diastolic
wall stress and not a substrate for neprilysin) and left atrial
(LA) size (as a potential marker of LA and LV end-diastolic
pressure).40
The active run-in period of PARADIGM-HF served two main
functions. First, both the enalapril and LCZ696 run-in periods max-
imized attainment of the target doses of each drug which is import-
ant as outlined above. The LCZ696 run-in period also provided
investigator-unblinded, albeit short-term, safety information on
the ARNI, which was important in light of the limited data on
tolerability of LCZ696 in patients with heart failure available
before PARADIGM-HF commenced—in essence the development
programme for LCZ696 in systolic heart failure bypassed the
typical ‘Phase II’ development stage. The decision to do this,
rather than conduct an initial ‘stand-alone’ Phase II trial, was
based on substantial and reassuring safety experience with
LCZ696 in hypertension and prior experience with omapatrilat.
Furthermore, Phase II studies rarely predict success in Phase III
trials in heart failure and simply prolong the time and increase
the cost involved in making a definitive determination of the effi-
cacy and safety of a new treatment, which always requires a
large mortality/morbidity trial.
For safety reasons, there are also two short washout periods
during the run-in. These washout periods are designed to minimize
concomitant neprilysin and ACE inhibition which is likely to in-
crease the risk of angioedema. Although the risk of angioedema
is expected to be low, for the reasons outlined earlier,22 a
special committee of experts are adjudicating all cases of suspected
angioedema in PARADIGM-HF and other studies with LCZ696
(see Appendix 1).
The primary outcome of CV death or heart failure hospitalization
was chosen as the one that best reflects the major mortality
and morbidity burden of this syndrome and has been used in
other recent trials including CHARM-Added, SHIFT, and
EMPHASIS-HF.25,40,41 However, uniquely, PARADIGM-HF is
powered on the basis of CV mortality giving both adequate power
to detect a reduction in CV mortality and .97% power to detect
a clinically meaningful reduction in the primary composite
outcome. Two of the secondary and exploratory endpoints merit
a special mention. Decline in renal function is of interest given that
natriuretic peptides and neprilysin inhibition have been reported
to increase glomerular filtration and because renal impairment as
an adverse effect was less common with omaptrilat than with enala-
pril in OVERTURE.17,41,42 Similarly, development of diabetes is of
interest, given the recent suggestion that low natriuretic peptides
levels may be associated with the development of this disease and
omapatrilat improved glucose utilization peripherally.45,46
In summary, PARADIGM-HF is addressing, within a major clinic-
al outcome trial, the place of the ARNI LCZ696 as an alternative to
the ‘gold-standard’ ACE inhibitor enalapril in patients with chronic
systolic heart failure. As the largest clinical trial in heart failure to
date, PARADIGM-HF may change our approach to neurohumoral
modulation in heart failure.
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